Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Tuesday, June 30
POSTE SESOS TrckA 120-221., rakB211221

21206 Construction and characterization of recombinant BCG-vectored vaccine
against HIV-1 clade E strain
Kazuhiro Matsuo* H. Yoshizaki; K. Someya; S. Naganawa; H. Yoshikura;
S. Yamazaki; M. Honda, Japan
21207 Antigenicity of HIV-1 envelope glycoproteins from either primary
isolates or T-cell lines adapted strains expressed using a Semliki Forest
Virus vector
Denys Brand*; F. Lemiale; G. Thibault; B. Verrier; F. Barin, France
21208 Development of rationally designed vaccines for HIV-1 through the use
of molecular adjuvants
long Joseph Kim*; D.B. Weiner, USA
21209 Effects of a PPD-pentavalent V3 loop penta-peptide conjugate vaccine
on reduction of viral loads and HIV V3 sequence in HIV+ subjects
Arye Rubinstein* Y. Mizrachi;J. Lenz; M. Pettoello-Mantovani; G.Q. Liu;
H. Goldstein; I. Yust; M. Burke; N. Vardinon;Z. Spirer; SJ. Cryz, USA
21210 HIV-negative infants born to HIV-1 but not HIV-2 positive mothers fail to
develop a BCG scar
Martin Ota*; D. O'Donovan; A. Marchant; S. Jaffar; K.P. W. Mcadam;
T. Corrah; H.C. Whittle, The Gambia
21211 Three types of env and gag-containing plasmids for DNA immunization
against HIV-1
Jun Fukushima* K.H. Hamajima; T.Y. Yokohama; S.K. Kawamoto;
K.N. Nishioka; K.O. Okuda, Japan
21212 Effect of a gp 120-depleted inactivated HIV-1 immunogen (REMUNET)
on the control of nuclear factor kappa-B activation and cytokine
production in primary human T cells
Eduardo Fernandez-Cruz*; M.A. Muhoz Fernandez; J. Navarro Caspistegui;
J.L. Jimenez Fuentes; M.L. AbadAlastruey, Spain
21213 Intranasal administration may be one of ideal immunizing route for
HIV-1 DNA vaccine
Kenji Hamajima*;J.-F. Fukushima; S.-S. Sasaki; K.-X. Xin; T.-K. Kaneko;
S.-K. Kawamoto; K.-O. Okuda, Japan
21214 Neutralizaion of macrophage and T cell line tropic viruses by a bivalenet
subtype B/E vaccine designed for Asia
Phillip Berman*; W. Huang; L. Riddle; T. Wrinn; D. Francis; M. Clasen;
T.J. Gregory, USA
21215 Lymphocyte proliferative response following immunization with a novel
HIV-1 V3 recombinant multi-epitope polypeptide:TAB 9
Beatriz C. Sierra*; S. Resik; A.B. Perez; V. Kouri; C. Duarte, Cuba
21216 Multi-Epitope polypeptide TAB9 adjuvated with Montanide ISA720 is
highly immunogenic and induces neutralizing antibodies in macaques
Carlos A. Duarte*; C.E. Gomez; L. Navea; L. Lobaina, Cuba
Track B: Clinical Science and Care
22101 Detection by PCR oftreponema pallidum DNA in cerebrospinal fluid from
HIV patients with neurological diseases
Pasquale Noto*; Maria Grazia Paglia; B.E. Boumis; F.A. Frigiotti;
D.F.A. de Felici; G.P. Guaraseio; G.A. Giurin; D.A.E. D'Amato, Italy
22102 Nosocomial bloodstream infections in HIV+ patients. Attributable
mortality and excess of hospital stay

Mario Tumbarello*; E. Tacconelli; K. De Gaetano; F Leone; G. Morace; R.
Cauda; L. Ortona

22103 Effect of highly aggressive antiretroviral therapy on the incidence of
bacteraemia in HIV+ patients
E. Tacconelli; M. Tumbarello; K. De Gaetano; F. Leone; R. Cauda; L. Ortona
22104 The incidence and risk factors for bacterial pneumonia among HIVinfected persons - United States
John Ward*; D. Hanson; M. Dworkin; J.L. Jones, USA
22105 Morbidity associated with long-term use of subcutaneous venous
reservoirs in patients with AIDS
Judith Torimiro*; N.E. Mpoudi; L. Ntsama, Cameroon
22106 Central venous catheters (Cvc)-related bacteraemia In HIV+ Subjects:
3 years prospective survey
Katleen De Gaetano; E. Tacconelli; M. Tumbarello; M. Pittiruti; F. Leone;
R. Cauda; L. Ortona
22107 Emerging gram-negative bacterial pathogens in the setting of HIV
disease: frequency and clinical significance
Roberto Manfredi*; F. Chiodo, Italy
22108 HIV-associated pneumonias: The efficacy of pneumococcal vaccine (PV)
Gildon Beall*; Mario Guerrero; S. Kruger; A. Saitoh; F. Sorvillo; K.J. Cheng;
G. Beall; C. French, USA
22109 Community acquired bacteremia and mycobacteremia in febrile adults
admitted to Mulago hospital in Kampala, Uganda
Moses R. Kamya*; S.N. Ssali; F. Wabire-Mangen; S. Kasasa; M. Joloba;
R. Mugerwa;J.L. Johnson, Uganda
22110 Community-acquired bacteremia in HIV-infected patients
ElkeJonnyMutschelknauss*; C. Leen; X. Emmanuel; A. Wilson;
S. Povey; R.P. Brettle, UK
22111 Rhodococcus equi infection in AIDS patients. GESEDA and GAEI study
Julio Arriz Abalaga*; M. Torre's Tortosa; E. Valencia; J. Galvez; C. Quereda;
M. Leyes; Gesiday Gaei Study, Spain
22112 Invasive salmonella species and HIV-infection
Heather H. Crewe-Brown*; A.S. Karstaedt; G.L. Saunders; M. Khoosal;
K. McCarthy, South Africa
22113 Streptococcus pneumoniae and pneumocystis carinii co-infection:
A case-control study in AIDS patients
Olivier Rutschmann*; Anne Auckenthaler-Mendoula; P. Sudre;
B. Hirschel, Switzerland
22114 Bacillary angiomatosis in the setting of clarithromycin and highly active
antiretroviral therapy (HAART)
James Witek*; A.J. Sigler; M.J. Gold, USA
22115 Helicobacter pylori: A potentially unrecognized health threat to HIV+
individuals in developing countries?
Carol Palmer*; J.M. Dubon; W.I. Klaskala; R. Garcia-Bernal; E.R. Garcia;
M.K. Baum; A.L. Ager, USA
22116 Diagnosis and treatment for community-acquired pneumonia (CAP)
among Ugandan adults: Impact of HIV-infection
Hiroyuki Yoshimine*; K.O. Oishi; F.M. Mubiru; H.N. Nalwoga;
H.T. Takahashi; R.M. Mugerwa; T.N. Nagatake, Japan
22117 High prevalence of co-trimoxazole resistent strains in community
acquired bacterial pneumonia in patients with advanced HIV disease
Evangelo Boumis*; P NOto; P Guarascio; F. Leoni; E. Girardi; G. De Carli;

C. D'Amato, Italy

82

12th World AIDS Conference Geneva